Related Experiment Video

Updated: Jul 5, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

CYP17 inhibitors for prostate cancer treatment--an update

V M Moreira1, J A R Salvador, T S Vasaitis

  • 1Laboratório de Química Farmacêutica, Faculdade de Farmácia, Universidade de Coimbra, Rua do Norte, 3000-295 Coimbra, Portugal.

Current Medicinal Chemistry
|May 14, 2008
PubMed

Insights

This review explores cytochrome 17alpha-hydroxylase-C(17,20)-lyase (CYP17) inhibitors for prostate cancer (PC) treatment. It highlights advancements in developing steroidal and nonsteroidal inhibitors to target PC progression.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Biochemistry

Background:

  • Androgens are crucial for prostate cancer (PC) growth, a fact known for nearly 70 years.
  • Ketoconazole has been used for PC therapy for approximately 30 years.
  • Cytochrome 17alpha-hydroxylase-C(17,20)-lyase (CYP17) inhibition is a key strategy in PC management.

Purpose of the Study:

  • To review the development of CYP17 inhibitors for prostate cancer treatment.
  • To explore both steroidal and nonsteroidal inhibitor candidates.
  • To provide insight into PC pathophysiology and treatment strategies.

Main Methods:

  • Literature review spanning nearly four decades.
  • Focus on identifying prospective CYP17 inhibitors.
  • Analysis of achievements in the absence of a 3D enzyme structure.

Main Results:

  • Significant progress has been made in identifying potential CYP17 inhibitors.
  • Development of both steroidal and nonsteroidal compounds targeting CYP17.
  • Understanding of PC pathophysiology has advanced.

Conclusions:

  • CYP17 inhibition represents a promising therapeutic avenue for prostate cancer.
  • Continued research into novel CYP17 inhibitors is essential for improving PC management.
  • This review offers insights into PC treatment options and future directions.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...